期刊
CHEMICAL SOCIETY REVIEWS
卷 50, 期 6, 页码 3647-3655出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/d0cs01118e
关键词
-
资金
- South African Medical Research Council (MRC)
- South African National Department of Health
- UK Government's Newton Fund
- UK Engineering and Physical Sciences Research Council EQATA
- UK Global Challenge Research Fund
- University of Cape Town
- South African Research Chairs Initiative of the Department of Science and Innovation [UID: 64767, UID: 87583]
- UKMRC [CVG-1725-2020]
- UKRI-DHSC [MR/Vo28464/1]
- MRC [MR/V028464/1] Funding Source: UKRI
Currently, only 10 out of over 220 known human-infecting viruses have clinically approved antiviral drugs. The COVID-19 outbreak highlights the critical need for compounds that can be quickly deployed for treating re-emerging or emerging viral diseases, while vaccines are being developed. Progress has been made in antiviral drug discovery for RNA viruses, but challenges remain in accelerating drug discovery efforts.
Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据